Balversa 5 mg (Erdafitinib TABLET) 5 MG

BALVERSA 5 MG tablets contain erdafitinib, a targeted therapy option for specific cancer treatments. Learn about its uses, effects, and precautions.

Strength

5 MG

Manufacturer / TM Owner

JANSSEN INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

BALVERSA 5 MG tablets are primarily used in the treatment of certain types of cancer. Erdafitinib, the active ingredient, is designed to target specific genetic mutations. This medication is often prescribed for conditions where these mutations play a significant role. Patients and healthcare providers should discuss the suitability of BALVERSA 5 MG for individual cases.

Side Effects

Common effects of BALVERSA 5 MG tablets may include fatigue, nausea, and changes in appetite. Some users might experience skin-related side effects. It's important to monitor any unusual symptoms and consult a healthcare professional if concerns arise.

Precautions & Warnings

BALVERSA 5 MG tablets should be handled with care, following the guidance of a healthcare provider. It is essential to store the medication properly and adhere to the prescribed usage. Patients with pre-existing conditions or allergies should inform their healthcare provider before starting treatment.

Avoid Interactions

BALVERSA 5 MG tablets may interact with certain medications, including those metabolized by specific liver enzymes. Alcohol and other substances might also affect the efficacy or safety of erdafitinib. Always inform your healthcare provider about all medications and supplements you are taking.

Frequently Asked Questions

BALVERSA 5 MG tablets are used in the treatment of certain types of cancer, targeting specific genetic mutations.

BALVERSA 5 MG tablets are taken orally, typically as prescribed by a healthcare provider.

Common side effects may include fatigue, nausea, and skin-related issues. Always consult a healthcare professional for personalized advice.

BALVERSA 5 MG may interact with certain medications. It's important to discuss all current medications with a healthcare provider.

Precautions include proper storage, adherence to prescribed usage, and informing your healthcare provider of any pre-existing conditions or allergies.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.